Abstract
Cathepsin K, a cysteine protease of the papain family, was identified by sequencing complementary DNA libraries derived from osteoclasts. Cathepsin K can cleave bone proteins such as Type I collagen, osteopontin, and osteonectin. The localization and maturation of cathepsin K in activated osteoclasts have been characterized. Furthermore, mutation of the gene expressing cathepsin K in humans results in pycnodysostosis, an autosomal recessive condition, resulting in osteopro-sis and increased bone fragility. Knockout of cathepsin K in the mouse also results in retarded bone matrix degradation and osteopetrosis. Together, these data demonstrate that inhibition of cathepsin K should result in a dimunition of osteoclast-mediated bone resorption. Several novel classes of cathepsin K inhibitors have been designed from X-ray co-crystal structures of peptide aldehydes bound to papain. The convergence of the design of novel inhibitors and the discovery of cathepsin K has created opportunities to further understand bone and cartilage biology as well as provide new therapeutic agents for the treatment of disease states in man such as osteoporosis.
Keywords: cathepsin K, Design Inhibitors, cysteine protease, Sequencing complementary DNA, osteoclasts, Type 1 collagen, osteonectin, pycndoysostosis, osteoprosis, osteoclast mediated bone resorption, xray co crystal structures, peptide aldehydes, RANK protein, homeostasis, integrin, NF kB, cDNA, Expression, interstitial collagenase activity, deficiency, irreversible cysteine protease inhibitors, azapeptides, acyloxymethylketones, SAR Peptide aldehydes vs, histocompatability complex MHC, papain, trypsin
Current Pharmaceutical Design
Title: Cathepsin K and the Design of Inhibitors of Cathepsin K
Volume: 6 Issue: 1
Author(s): Dennis S. Yamashita and Robert A. Dodds
Affiliation:
Keywords: cathepsin K, Design Inhibitors, cysteine protease, Sequencing complementary DNA, osteoclasts, Type 1 collagen, osteonectin, pycndoysostosis, osteoprosis, osteoclast mediated bone resorption, xray co crystal structures, peptide aldehydes, RANK protein, homeostasis, integrin, NF kB, cDNA, Expression, interstitial collagenase activity, deficiency, irreversible cysteine protease inhibitors, azapeptides, acyloxymethylketones, SAR Peptide aldehydes vs, histocompatability complex MHC, papain, trypsin
Abstract: Cathepsin K, a cysteine protease of the papain family, was identified by sequencing complementary DNA libraries derived from osteoclasts. Cathepsin K can cleave bone proteins such as Type I collagen, osteopontin, and osteonectin. The localization and maturation of cathepsin K in activated osteoclasts have been characterized. Furthermore, mutation of the gene expressing cathepsin K in humans results in pycnodysostosis, an autosomal recessive condition, resulting in osteopro-sis and increased bone fragility. Knockout of cathepsin K in the mouse also results in retarded bone matrix degradation and osteopetrosis. Together, these data demonstrate that inhibition of cathepsin K should result in a dimunition of osteoclast-mediated bone resorption. Several novel classes of cathepsin K inhibitors have been designed from X-ray co-crystal structures of peptide aldehydes bound to papain. The convergence of the design of novel inhibitors and the discovery of cathepsin K has created opportunities to further understand bone and cartilage biology as well as provide new therapeutic agents for the treatment of disease states in man such as osteoporosis.
Export Options
About this article
Cite this article as:
Yamashita S. Dennis and Dodds A. Robert, Cathepsin K and the Design of Inhibitors of Cathepsin K, Current Pharmaceutical Design 2000; 6 (1) . https://dx.doi.org/10.2174/1381612003401569
DOI https://dx.doi.org/10.2174/1381612003401569 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epidemiological Features of the 2019 Novel Coronavirus Outbreak in China
Current Topics in Medicinal Chemistry Determination of Methanol in Commercialized Alcohol-based Hand Sanitizing and Other Similar Products using Headspace GC-MS
Current Analytical Chemistry COVID-19 Improved Diagnoses Based on the Open-morphology Filter and Deep-learning
Recent Patents on Engineering Nanotechnology-based Herbal Formulations: A Survey of Recent Patents, Advancements, and Transformative Headways
Recent Patents on Nanotechnology Recent Development of Peptide Drugs and Advance on Theory and Methodology of Peptide Inhibitor Design
Medicinal Chemistry Biochemical, Biomedical and Metabolic Aspects of Imidazole-Containing Dipeptides with the Inherent Complexity to Neurodegenerative Diseases and Various States of Mental Well-Being: A Challenging Correction and Neurotherapeutic Pharmaceutical Biotechnology for Treating Cognitive Deficits, Depression and Intellectual Disabilities
Current Pharmaceutical Biotechnology Discovery and Development of Endocannabinoid-Hydrolyzing Enzyme Inhibitors
Current Topics in Medicinal Chemistry Oxocarbon Acids and their Derivatives in Biological and Medicinal Chemistry
Current Medicinal Chemistry Expression and Functions of Vasoactive Substances Regulated by Hypoxia-Inducible Factor-1 in Chronic Hypoxemia
Cardiovascular & Hematological Agents in Medicinal Chemistry The Use of Flavonoids in Central Nervous System Disorders
Current Medicinal Chemistry Design, Synthesis and Antiproliferative Activity of Novel Benzothiazole Derivatives Conjugated with Semicarbazone Scaffold
Medicinal Chemistry Pathophysiology of Cardiac Cell Injury in Post-COVID-19 Syndrome
New Emirates Medical Journal Technology-Dependent Children: The Chronically Ventilated Child
Current Pediatric Reviews MicroRNAs in Prostate Cancer Following Radiotherapy: Towards Predicting Response to Radiation Treatment
Current Medicinal Chemistry Phosphodiesterase 10 Inhibitors: New Disease Modifying Drugs for Parkinson’s Disease?
Current Medicinal Chemistry Insights into the Structural Complexities of SARS-CoV-2 for Therapeutic and Vaccine Development
Combinatorial Chemistry & High Throughput Screening Efficacy of Lopinavir/Ritonavir Compared With Standard Care for Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review
Infectious Disorders - Drug Targets Nano-Engineered Environment for Nerve Regeneration: Scaffolds, Functional Molecules and Stem Cells
Current Stem Cell Research & Therapy Synthesis, Molecular Docking and Pharmacological Study of Pyrimidothiadiazinones and its bis-derivatives
Letters in Drug Design & Discovery Bioisosteric Replacement and Related Analogs in the Design, Synthesis and Evaluation of Ligands for Muscarinic Acetylcholine Receptors
Medicinal Chemistry